Deals should be treated uniquely, taking into account their investment hypothesis, motivation and capabilities of stakeholders, market dynamics at the time of the deal and drivers for timing to close.

Arda Ural, PhD

EY Americas Life Sciences Leader

Frequent speaker about biopharmaceutical strategy at industry conferences. Married father of two.

As EY Americas Life Sciences Leader, Arda serves EY life sciences professionals across the Americas, helping them solve clients’ most pressing issues at the C-suite level.

Arda has a track record in pharma, biotech and medtech with 30 years of experience in general management, corporate strategy, commercialization, new product development, artificial intelligence-led business transformation and M&A.

Prior to joining EY, Arda was a Managing Director at a leading strategy firm. Earlier, Arda worked as a VP of Strategic Marketing and a BU Lead at a Fortune 500 medical technology company. He also served as the SVP Marketing & Sales for a startup biotechnology company. Arda started his career at a pharmaceutical company.

Arda was named a “Standout Leader” in the 2024 PharmaVoice 100. He is a frequent speaker at conferences, author of numerous thought pieces and is regularly interviewed by the media.

How Arda is building a better working world

“We live in a rapidly changing and inter-connected life sciences ecosystem. I work with our pharma, medtech, biotech and Private Equity clients to determine paths for value generation after taking into account both macro trends and company specific fundamentals across a broad spectrum of variables to bring meaningful impact to getting treatments to patients..”

Arda’s latest thinking